Mindful Innovation

Inspired by the urgent needs of children with cancer, Day One creatively and intentionally develops new medicines for people of all ages living with life-threatening diseases

FIREFLY-2:

Tovorafenib, an investigational, oral, pan-RAF inhibitor versus standard of care chemotherapy being studied in pediatric patients with RAF-altered low-grade glioma requiring front-line systemic therapy

Learn about Firefly-2

DAY301-001:

DAY301-001 is a phase 1, open label study of the PTK7-targeted antibody-drug conjugate (ADC) DAY301 in patients ≥18 years of age with locally advanced or metastatic solid tumors

Learn about DAY301-001

FIREFLY-1:

Tovorafenib, an investigational, oral, pan-RAF inhibitor being studied in pediatric patients with recurrent or progressive low-grade glioma and advanced solid tumors with RAF alterations

Learn about Firefly-1

Interested in learning more?

For clinical trial information, please email [email protected]
For medical inquiries in the US, please email [email protected]